Browse > Article
http://dx.doi.org/10.14368/jdras.2014.30.4.299

The prevention of mortality after botulinum toxin injection in oral maxillofacial region  

Lee, Won-Kang (Department of Orofacial Pain & Oral Medicine, College of Dentistry, Yonsei University)
Choi, Young-Chan (Department of Orofacial Pain & Oral Medicine, College of Dentistry, Yonsei University)
Choi, Moon-Jong (Sarangmaeul Psychiatric Clinic)
Kim, Seong-Taek (Department of Orofacial Pain & Oral Medicine, College of Dentistry, Yonsei University)
Publication Information
Journal of Dental Rehabilitation and Applied Science / v.30, no.4, 2014 , pp. 299-306 More about this Journal
Abstract
Botulinum toxin (BoNT) has been used for a wide spectrum of therapeutic and cosmetic indications, and the range of indications is continually increased. Though BoNT is a powerful poison, the fact that not only the effect but also the adverse effect of it fader about 6 months after injection makes clinicians to neglect its dangerous property in clinical application. But Many reports about the adverse effects including death of BoNT injection have been reported, the FDA edited in additional warnings about hospitalizations and deaths. In this study, we intended to look through the metabolic process in human body, possible adverse effect, matters to be attended in application, and cases reports about deaths of BoNT by reviewing the previous studies.
Keywords
botulinum toxin; metabolic process; adverse effects; death;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Al-Saleem FH, Ancharski DM, Ravichandran E, Joshi SG, Singh AK, Gong Y, Simpson LL. The role of systemic handling in the pathophysiologic action of botulinum toxin. J Pharmacol Exp Ther 2008;326:856-63.   DOI   ScienceOn
2 Al-Saleem FH, Nasser Z, Olson RM, Cao L, Simpson LL. Identification of the factors that govern the ability of therapeutic antibodies to provide postchallenge protection against botulinum toxin: a model for assessing postchallenge efficacy of medical countermeasures against agents of bioterrorism and biological warfare. J Pharmacol Exp Ther 2011;338:503-17.   DOI   ScienceOn
3 Sheth AN, Wiersma P, Atrubin D, Dubey V, Zink D, Skinner G, Doerr F, Juliao P, Gonzalez G, Burnett C, Drenzek C, Shuler C, Austin J, Ellis A, Maslanka S, Sobel J. International outbreak of severe botulism with prolonged toxemia caused by commercial carrot juice. Clin Infect Dis 2008;47:1245-51.   DOI   ScienceOn
4 Koriazova LK, Montal M. Translocation of botulinum neurotoxin light chain protease through the heavy chain channel. Nat Struct Biol 2003;10:13-8.   DOI   ScienceOn
5 Dolimbek BZ, Aoki KR, Steward LE, Jankovic J, Atassi MZ. Mapping of the regions on the heavy chain of botulinum neurotoxin A (BoNT/A) recognized by antibodies of cervical dystonia patients with immunoresistance to BoNT/A. Mol Immunol 2007;44:1029-41.   DOI   ScienceOn
6 Goschel H, Wohlfarth K, Frevert J, Dengler R, Bigalke H. Botulinum A toxin therapy: neutralizing and non-neutralizing antibodies-therapeutic consequences. Exp Neurol 1997;147:96-102.   DOI   ScienceOn
7 Lange O, Bigalke H, Dengler R, Wegner F, deGroot M, Wohlfarth K. Neutralizing antibodies and secondary therapy failure after treatment with botulinum toxin type A: much ado about nothing? Clin Neuropharmacol 2009;32:213-8.   DOI   ScienceOn
8 Naumann M, Boo LM, Ackerman AH, Gallagher CJ. Immunogenicity of botulinum toxins. J Neural Transm 2013;120:275-90.   DOI   ScienceOn
9 Cote TR, Mohan AK, Polder JA, Walton MK, Braun MM. Botulinum toxin type A injections: adverse events reported to the US Food and Drug Administration in therapeutic and cosmetic case. J Am Acad Dermatol 2005;53:407-15.   DOI   ScienceOn
10 Simpson L. The life history of a botulinum toxin molecule. Toxicon 2013;68:40-59.   DOI   ScienceOn
11 Lamanna C. The most poisonous poison. Science 1959;130:763-72.   DOI   ScienceOn
12 Simpson LL. Identification of the major steps in botulinum toxin action. Annu Rev Pharmacol Toxicol 2004;44:167-93.   DOI   ScienceOn
13 Elias M, Al-Saleem FH, Ancharski DM, Singh A, Nasser Z, Olson RM, Simpson LL. Evidence that botulinum toxin receptors on epithelial cells and neuronal cells are not identical: implications for development of a non-neurotropic vaccine. J Pharmacol Exp Ther 2011;336:605-12.   DOI   ScienceOn
14 Ravichandran E, Gong Y, Al-Saleem FH, Ancharski DM, Joshi SG, Simpson LL. An initial assessment of the systemic pharmacokinetics of botulinum toxin. J Pharmacol Exp Ther 2006;318:1343-51.   DOI   ScienceOn